Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01370148
Other study ID # 087-CL-099
Secondary ID
Status Completed
Phase Phase 1
First received June 8, 2011
Last updated April 30, 2014
Start date April 2011
Est. completion date February 2014

Study information

Verified date April 2014
Source Cumberland Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour continuous infusion of conivaptan in subjects with severe liver impairment compared to subjects with normal liver function.


Description:

Subjects will be admitted to the Phase 1 unit Day -2 and will remain confined to the unit until discharge on Study Day 5 after completion of all study procedures.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date February 2014
Est. primary completion date February 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria:

Subjects with Normal Hepatic Function:

Female subject must be either:

- post-menopausal prior to Screening, or

- premenarchal prior to Screening, or

- documented surgically sterile or post hysterectomy, or

- if of childbearing potential, must have a negative pregnancy test at Screening and must be using highly effective contraception prior to Screening and throughout the study period and for 28 days after final study drug administration

- Female subject must not be lactating and must not be breastfeeding at Screening or during the study period, and for 28 days after final study drug administration

- Female subject must not donate ova starting at Screening or during the study period, and for 28 days after final study drug administration

- Male subject must:

- be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 28 days after final study drug administration

- not donate sperm starting at Screening and throughout the study period, and for at least 28 days after final study drug administration

- Subject weighs at least 45 kg and has a body mass index between 18 and 40 kg/m2 inclusive

- The subject must have clinical laboratory test results within normal range, including liver function tests (LFTs)

- The subject must have had a normal 12-lead electrocardiogram (ECG)

Hepatic Impaired Subjects:

- Female subject must be either:

- post-menopausal prior to Screening, or

- premenarchal prior to Screening, or

- documented surgically sterile or post hysterectomy, or

- if of childbearing potential, must have a negative pregnancy test at Screening and must be using highly effective contraception prior to Screening and throughout the study period and for 28 days after final study drug administration

- Female subject must not be lactating and must not be breastfeeding at Screening or during the study period, and for 28 days after final study drug administration

- Female subject must not donate ova starting at Screening or during the study period, and for 28 days after final study drug administration

- Male subject must:

- be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 28 days after final study drug administration

- not donate sperm starting at Screening and throughout the study period, and for at least 28 days after final study drug administration

- Subject meets criteria for severe hepatic impairment defined by Child-Pugh method

- Subject weighs at least 45 kg and has a body mass index between 18 and 40 kg/m2 inclusive

- The subject must have clinical laboratory test results within therapeutic range except for hepatic disease

- The subject must have had a normal 12-lead electrocardiogram (ECG)

Exclusion Criteria:

Subjects with Normal Hepatic Function:

- Subject has a history of a clinically significant illness, and associated clinical symptoms, medical condition, or laboratory abnormality within past 3 months that would preclude participation in the study

- Subject has evidence of biliary obstruction or other causes of hepatic impairment

- Subject is known to have hepatitis or is a carrier of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or is known to be HIV positive or has HIV antibodies

- Subject has an impaired ability to sense thirst

- Subject has serum sodium less than 115mEg/L or greater than 140 mEg/L

- Subject has either a systolic blood pressure (BP) of greater than 140 mmHg or a diastolic BP of less than 56 mmHg

- Subject has taken any prescription or over-the-counter medications except for contraceptives, hormone replacement therapy and occasional acetaminophen, or alternative and complementary medicines within past 14 days

- Subject has a history of carcinoma, except for basal cell or cutaneous squamous cell carcinoma within past 5 years

- Subject drinks greater than 14 units of alcohol per week (Note: one unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits)

- Subject has a history of substance abuse within past 6 months prior to Screening Visit or the subject tests positive at Screening or clinic admission for alcohol or drugs of abuse

- Subject is currently participating in another clinical trial or has received an investigational medication within past 30 days

- Subject is known to have hypersensitivity to conivaptan or its derivatives

- Subject has had a blood transfusion or donated/lost more than 550ml of blood within past 8 weeks

- Subject is incapable of being compliant with the protocol

Subjects with Hepatic Impairment:

- Subject has a history of a clinically significant illness, and associated clinical symptoms, medical condition, or laboratory abnormality within past 3 months that would preclude participation in the study. Subjects with controlled hypertension may be allowed

- Subject has a condition associated with hepatic disease including; biliary obstruction, or other cause of hepatic impairment not related to parenchymal disorder and/or disease of the liver, fluctuating or rapidly deteriorating hepatic function, biliary liver cirrhosis, history or presence of hepatic encephalopathy greater than Grade 1 within past 3 months or unstable encephalopathy prior to Screening, tense ascites, esophageal/gastric variceal bleeding with past 6 months, server portal hypertension, surgical portal systemic shunt or peritoneal venous shunt, thrombocyte level below 50,000 x 10^9/L and prothrombin time (PT) above 18 seconds

- Subject is hypovolemic or has evidence of orthostatic hypotension

- Subject has an impaired ability to sense thirst

- Subject has serum sodium less than 115mEg/L or greater than 140 mEg/L

- Subject has either a systolic blood pressure (BP) of greater than 140 mmHg or a diastolic BP of less than 56 mmHg

- Subject is known to be HIV positive or has HIV antibodies

- Subject has had a change in dose regimen of medication needed for their underlying medical condition with the past four weeks

- Subject is currently taking a prohibited medication

- Subject drinks greater than 14 units of alcohol per week (Note: one unit equals 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits)

- Subject has a history of substance abuse within past 6 months prior to Screening Visit or the subject tests positive at Screening or clinic admission for alcohol or drugs of abuse

- Subject is currently participating in another clinical trial or has received an investigational medication with past 30 days

- Subject has had a blood transfusion or donated/lost more than 550ml of blood within past 8 weeks

- Subject is known to have hypersensitivity of conivaptan or its derivatives

- Subject is incapable of being compliant with the protocol

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
conivaptan hydrochloride
Intravenous

Locations

Country Name City State
United States Advanced Clinical Research Institute Anaheim California
United States DaVita Clinical Research Lakewood Colorado
United States Orlando Clinical Research Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
Cumberland Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the effect of severe hepatic impairment on the plasma drug concentration of conivaptan through analysis of blood samples 5 days Yes
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT01968395 - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Phase 4
Completed NCT01437969 - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting NCT00155376 - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Phase 4
Recruiting NCT00172705 - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique N/A
Completed NCT04185454 - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese N/A
Completed NCT02506335 - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease Early Phase 1
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed NCT02306018 - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation N/A
Completed NCT01970904 - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients N/A
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00245830 - Ischemic Preconditioning of Liver in Cadaver Donors N/A
Completed NCT00074386 - Kidney and Liver Transplantation in People With HIV N/A
Completed NCT02329821 - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection N/A
Completed NCT01650181 - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Phase 4
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Completed NCT00799851 - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Phase 4
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3